ClinicalTrials.gg
CompletedNCT01452607Updated Jun 29, 2016

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

A Phase 1 interventional study of SPI-1005 and Placebo in Hearing Loss and Cancer, sponsored by Sound Pharmaceuticals, Incorporated. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-29.

Sponsored by Sound Pharmaceuticals, Incorporated · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 321 studies in Hearing Loss with a site in United States — 82 open to participants now, 94 under way, 3 of them phase 3. Hearing Loss · United States.

Enrollment
172nd of 272
32 · median 48
Started
2006
with 7 others
Phase 1
19 of 321
4 open now
Registered
55th of 321
by date
Lead sponsor
9 of 321
Sound Pharmaceuticals, Incorporated

Among the 321 studies in Hearing Loss with a site in United States, this one is the 172nd largest by enrollment of the 272 interventional ones that give a count, is one of 8 that started in 2006, is one of 19 in phase 1, and was the 55th registered.

Hearing Loss

796 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

82 of the 321 studies in Hearing Loss with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 42 (34%) stop at 75 or younger; 46 take children under 18; 46 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Hearing Loss with a site in United States, or all of them as a file.
02

Study summary

A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.

03

Conditions studied

  • Hearing Loss
  • Cancer

Keywords

  • Ebselen
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male and female subjects
  • Within 15% of their ideal weights (Table of "Desirable Weights of Adults," Metropolitan Life Insurance Company, 1983)
  • Medically healthy subjects with clinically insignificant screening results (laboratory profiles, medical histories, ECGs, physical exam);
  • Voluntarily consented to participate in the study;
  • Females of were either sexually inactive (abstinent) for 14 days prior to screening and throughout the study or used one of the following acceptable methods: Intrauterine device (IUD) in place for at least 3 months prior to study; Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; Stable hormonal contraceptive for at least 3 months prior to study through completion of study; Surgical sterilization (vasectomy) of partner at least 6 months prior to study. Females of non-childbearing potential were surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral oophorectomy at least 2 months prior to study).

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, otologic, or psychiatric disease;
  • History or presence of alcoholism or drug abuse within the past 2 years;
  • or idiosyncratic reaction to compounds related to ebselen;
  • Use of any prescription medication within 14 days (with the exception of hormonal ) prior to or during the study;
  • Use of any over-the-counter medication including vitamins, herbal preparations, antacids, cough and cold remedies, etc., within 7 days prior or during the study;
  • Use of any drugs or substances known to be strong inhibitors or inducers of cytochrome P450 enzymes within 28 days prior to dosing;
  • Abnormal diet (for any reason) during the 30 days prior to dosing;
  • Donation of whole blood within 56 days prior to the study;
  • Plasma donation within 7 days prior to the study;
  • Participation in another clinical trial within 30 days prior to the study;
  • Female subjects who were pregnant or lactating;
  • \< 12.0 g/dL;
  • Orthostatic vital signs which result in: A pulse increase of more than 30 beats per minute after 3 minutes standing (compared with semi-recumbent pulse rate); or A pulse rate greater than 100 bpm after 3 minutes standing; or A drop in systolic blood pressure decrease of at least 20 mm Hg; or A diastolic blood pressure decrease of at least 10 mm Hg within 3 minutes of standing (compared with semi-recumbent blood pressure).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    SPI-1005 Capsule 200mg Ebselen x1

    Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose

    Drug: SPI-1005

  • Experimental
    SPI-1005 Capsule 200mg Ebselen x2

    2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose

    Drug: SPI-1005

  • Experimental
    SPI-1005 Capsule 200mg Ebselen x4

    4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose

    Drug: SPI-1005

  • Experimental
    SPI-1005 Capsule 200mg Ebselen x8

    8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose

    Drug: SPI-1005

  • Placebo comparator
    SPI-1000 Capsule 0 mg Ebselen Placebo

    Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose

    Drug: Placebo

Interventions

  • 200 mg Ebselen oral capsules (SPI-1005), single dose

    Also known as: 200 mg Ebselen

  • DrugPlacebo

    0 mg Ebselen oral capsules (SPI-1000), single dose

    Also known as: 0 mg Ebselen

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    The primary objective of this study was to evaluate the safety and tolerability of SPI-1005 (ebselen) in healthy subjects. Incidence and severity of Adverse Events were determined in all treatment and placebo groups.

    Time frame: 1 month

Secondary outcomes

  1. Pharmacokinetics of SPI-1005 and its major metabolites in healthy subjects

    Evaluate the single dose pharmacokinetic profile of SPI-1005 in healthy subjects including Tmax, Cmax, of the parent compound and major metabolites.

    Time frame: 24 hours

07

Study locations

1 site
  • MDS Pharma Services
    Lincoln, Nebraska 68502, United States
08

References and documents

Publications

  • Lynch E, Kil J. Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing Loss. Semin Hear 2009; 30(1): 047-055
  • Garland M, Hryckowian AJ, Tholen M, Bender KO, Van Treuren WW, Loscher S, Sonnenburg JL, Bogyo M. The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI. Cell Rep Med. 2020 Apr 21;1(1):100005. doi: 10.1016/j.xcrm.2020.100005. PubMed 32483557 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2011
First posted
Oct 17, 2011
Start
May 2006
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Jun 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01452607
Lead sponsor
Sound Pharmaceuticals, Incorporated
Responsible party
Sponsor
First posted
Oct 17, 2011
Start date
May 2006
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Jun 29, 2016

Study contacts

James C. Kisicki, M.D.
principal investigator · MDS Pharma Services

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebselen

Start the discussion